The transaction is expected to close in the third quarter this year. As a combined company, it will have a total addressable market of approximately $70 billion and include more than 4,600 physician relationships in 38 states.
“With the addition of Sheridan, we will be significantly diversified and differentiated — holding leadership positions in outsourced physician services for anesthesia, children’s services, emergency medicine services and radiology while retaining our standing as a leading owner of freestanding ambulatory surgery centers,” said Christopher Holden, president and CEO of AmSurg, in a news release.
Sheridan is currently owned by private equity firm Hellman & Friedman. The company will be a “significant shareholder” of the combined company post-transaction, according to the release.
In April, Sheridan had announced it hired Credit Suisse Group, Barclays and Goldman Sachs to lead an initial public offering. It has been a private company since 1999.
More Articles on Sheridan Healthcare:
AmSurg to Buy Sheridan Healthcare: 5 Things to Know
3 Steps to do the Impossible With Physician-Led Teams
10 Things to Know About Sheridan Healthcare
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
